858-449-1310 contact@somatek.com

NEWS

CAR-T Cells: Cool new poster

Got empty wall space in your lab or hallway? Consider decorating with the new timely “Chimeric Antigen Receptor (CAR)-T Cell in Immunotherapy” poster available from Novus Biologicals.  https://www.novusbio.com This wall poster provides an overview of Chimeric Antigen...

read more

A novel recombinant protein for treatment of stroke

Stroke is the fifth leading cause of death in the United States and the number one cause of adult disability. Acute ischemic strokes occur when a clot blocks blood flow to the brain. To date, the FDA has approved only one drug treatment, called tissue plasminogen...

read more

FDA’s Top Ten Drug GMP Citations

At the FDA/Xavier University PharmaLink conference at Xavier University in Cincinnati, Ohio, in March 2017, FDA's Robert Tollefsen and Dell Moller presented the top ten drug GMP inspection citations for FY 2016. As summarized by Elanco's Brent Conatser these citations...

read more

Somatek launches new website

Somatek is pleased to announce the launch of its new website with improved functionality, fresh graphic design and new content. Many thanks to Sanne Wesselman and AtoZmarketing for expert support in setting up the new site. Please visit us often for updates and to see...

read more

FDA approves 19 biological licenses in 2017

This year FDA moved to approve 19 new biological licenses including biologics for the treatment of blood cancers and hemophilia. Notably, 2017 saw the approval of a new type of immunotherapy using genetically engineered, patient-derived T-cells, so-called CAR-T cells....

read more